ElectroPhysiology Frontiers (EPF) is a MedTech company that has developed an innovative, easy to use “single-shot” catheter ablation system to provide durable ablations and reduce the rate of recurrence of Atrial Fibrillation (AFib) after pulmonary vein isolation (PVI).

This unique catheter can be used for radiofrequency (RFA) and pulsed-field ablation (PFA) and was designed to simplify and optimize the efficiency of catheter ablation procedures for the treatment of AF. The catheter offers the promise for quick, effective and reproducible lesion delivery. The targeted market is huge, over $2B.

EPF is in Indaco Ventures I’s portfolio since 2019.